Analysts predict that Histogenics Corp (NASDAQ:HSGX) will report earnings per share (EPS) of ($0.31) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Histogenics Corp’s earnings. Histogenics Corp posted earnings of ($0.61) per share in the same quarter last year, which suggests a positive year over year growth rate of 49.2%. The business is expected to announce its next quarterly earnings results on Thursday, August 10th.

On average, analysts expect that Histogenics Corp will report full year earnings of ($1.65) per share for the current financial year, with EPS estimates ranging from ($1.99) to ($1.31). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.63) to ($0.79). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Histogenics Corp.

Histogenics Corp (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.07. During the same quarter in the previous year, the firm earned ($0.60) EPS.

A number of equities analysts have issued reports on HSGX shares. HC Wainwright set a $4.00 price target on shares of Histogenics Corp and gave the stock a “buy” rating in a research report on Monday, March 20th. Canaccord Genuity reissued a “buy” rating on shares of Histogenics Corp in a research report on Thursday, May 11th. Finally, Zacks Investment Research raised shares of Histogenics Corp from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $5.10.

Institutional investors have recently bought and sold shares of the stock. Sabby Management LLC raised its position in Histogenics Corp by 15.9% in the first quarter. Sabby Management LLC now owns 1,095,422 shares of the biotechnology company’s stock valued at $1,895,000 after buying an additional 150,531 shares during the period. Vanguard Group Inc. purchased a new position in Histogenics Corp during the first quarter valued at $481,000. Carl Domino Inc raised its position in Histogenics Corp by 2.8% in the first quarter. Carl Domino Inc now owns 89,400 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,400 shares during the period. Armistice Capital LLC raised its position in Histogenics Corp by 376.3% in the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the biotechnology company’s stock valued at $2,111,000 after buying an additional 998,645 shares during the period. Finally, Perceptive Advisors LLC purchased a new position in Histogenics Corp during the fourth quarter valued at $2,968,000. 45.98% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Analysts Expect Histogenics Corp (HSGX) Will Announce Earnings of -$0.31 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/05/26/analysts-expect-histogenics-corp-hsgx-will-announce-earnings-of-0-31-per-share.html.

Histogenics Corp (NASDAQ:HSGX) remained flat at $1.65 on Friday. 20 shares of the company traded hands. The stock’s market capitalization is $34.06 million. Histogenics Corp has a 52 week low of $1.45 and a 52 week high of $4.47. The stock has a 50 day moving average price of $1.71 and a 200-day moving average price of $1.77.

Histogenics Corp Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

12 Month Chart for NASDAQ:HSGX

Get a free copy of the Zacks research report on Histogenics Corp (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogenics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp and related companies with MarketBeat.com's FREE daily email newsletter.